Cell-Based Assay to Determine Type 3 Secretion System Translocon Assembly in Pseudomonas aeruginosa Using Split

Hanling Guo1, Emily J Geddes2, Timothy J Opperman2

  • 1Program in Molecular and Cellular Biology, University of Massachusetts, Amherst, Massachusetts 01003, United States.

ACS Infectious Diseases
|November 18, 2023
PubMed

Insights

A new assay detects the assembly of the Type 3 secretion system (T3SS) translocon in Pseudomonas aeruginosa. This tool aids in developing new drugs to combat dangerous, drug-resistant bacterial infections.

Area of Science:

  • Microbiology and Infectious Diseases
  • Molecular Biology
  • Drug Discovery

Background:

  • Multi-drug-resistant *Pseudomonas aeruginosa* is a significant threat in healthcare settings.
  • The Type 3 secretion system (T3SS) is a key virulence factor in *P. aeruginosa* pathogenesis.
  • T3SS translocon assembly is essential for virulence and a potential therapeutic target.

Purpose of the Study:

  • To develop a novel whole-cell-based assay for detecting T3SS translocon assembly.
  • To establish a high-throughput screening method for identifying inhibitors of T3SS assembly.

Main Methods:

  • Utilized a split NanoLuc luciferase reporter system for translocon assembly readout.
  • Developed a whole-cell assay to monitor the protrusion of PopD N-terminus into host cells.
  • Assessed assay performance using signal/noise ratio and Z'-factor for robustness.

Main Results:

  • The novel assay successfully detected functional T3SS translocon assembly.
  • Achieved a favorable signal/noise ratio of 13.6.
  • Demonstrated assay robustness with a Z'-factor of 0.67, suitable for high-throughput screening.

Conclusions:

  • A novel, robust whole-cell assay for T3SS translocon assembly has been developed.
  • This assay is suitable for high-throughput screening of small-molecule inhibitors.
  • The findings facilitate the development of new therapeutic strategies against *P. aeruginosa* infections.

Related Concept Videos